Nasdaq smmt.

Summit Therapeutics PLC (NASDAQ:SMMT)’s CEO Robert Duggan also bought a 376 million shares of the company during the same month at $1.05 per share. As of May 19, the stock is trading at $1.62.Avenue Therapeutics Inc (NASDAQ:ATXI)’s Major holders. Insiders own 18.50% of the company shares, while shares held by institutions stand at 9.14% with a share float percentage of 11.21%. Investors are also buoyed by the number of investors in a company, with Avenue Therapeutics Inc having a total of 17 institutions that hold shares in the ...Dec 20, 2021 · Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study ... Oxford, UK, and Cambridge, MA, US, 25 February 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, published preclinical data on SMT-571, a ...

For the three months ended September 30th, 2018 vs September 30th, 2017, Global Payments reported revenue of $857.67MM vs $1,038.91MM (down 17.44%) and analysts estimated basic earnings per share ...WebSummit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...

Oxford, UK, and Cambridge, MA, US, 6 December 2019 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces a proposed fundraising (the “Fundraising ...

Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision ...Menlo Park, California, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it is nearing the previously-announced ...OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular ...Phunware Inc (NASDAQ:PHUN)’s Major holders Insiders own 8.46% of the company shares, while shares held by institutions stand at 9.60% with a share float percentage of 10.48%. Investors are also buoyed by the number of investors in a company, with Phunware Inc having a total of 43 institutions that hold shares in the company.Summit Therapeutics Inc. (NASDAQ:SMMT) has the sixth position on our list of the ten best penny stocks to buy in September. It is a Cambridge, Massachusetts-based clinical-stage drug discovery and ...Web

The company earned $0.27 million during the quarter. Summit Therapeutics has generated ($1.55) earnings per share over the last year ( ($1.55) diluted earnings per share). Summit Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior ...

Conference Call to be Held at 9:00am ET. MENLO PARK, Calif.--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to ...

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call.WebOxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer and ...WebNov 30, 2023 · The stock price of Summit Therapeutics Inc (NASDAQ: SMMT) has surged by 3.33 when compared to previous closing price of 1.95, but the company has seen a 3.33% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-26 that Summit Therapeutics Inc., backed by biotech billionaire Bob Duggan, has transitioned […] Windtree Therapeutics, Inc. (NASDAQ:WINT), Kala Pharmaceuticals, Inc. (NASDAQ:KALA), Summit Therapeutics Inc. (NASDAQ:SMMT), and GreenLight Biosciences Holdings (NASDAQ:GRNA) are some great stocks ...WebSummit Therapeutics Inc. Common Stock (SMMT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Summit Therapeutics, Inc. (NASDAQ:SMMT) Q1 2023 Earnings Conference Call May 11, 2023 9:00 AM ET. Company Participants. Dave Gancarz - SVP, Stakeholder Relations, Business Development & Corporate ...Summit Therapeutics Inc. Common Stock (SMMT) Nasdaq Listed. DATA AS OF Nov 26, 2021. 0. Add to Watchlist. Add to Portfolio. SMMT SMMT HISTORICAL DATA. Create your Watchlist to save your favorite quotes on Nasdaq.com. Log in or create a free account to get started. Outsmart the market with Smart Portfolio analytical tools powered …Cambridge, Massachusetts, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Based on a thorough review of the design and enrollment status of two ongoing blinded Phase III Ri-CoDIFy trials, Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will combine its two blinded pivotal Phase III clinical trials evaluating ridinilazole versus …1 E. Duperchy et al. ECCMID 2021, abstract P02515; E. Duperchy et al. ECCMID 2021, abstract P03486; T. Avis et al. ECCMID 2021, abstract P03404.

Find the latest Insider Activity data for Summit Therapeutics Inc. Common Stock (SMMT) at Nasdaq.com.

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call.Dec 1, 2023 · Which Summit Therapeutics insiders have been buying company stock? The following insiders have purchased SMMT shares in the last 24 months: Ankur Dhingra ($217,390.39), Mahkam Zanganeh ($16,772,430.15), Manmeet Singh Soni ($4,999,999.20), and Robert W Duggan ($487,318,100.91). OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular ...Oxford, UK, and Cambridge, MA, US, 15 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, presented in vivo proof of concept data for ...Summit Therapeutics (NASDAQ:SMMT) is a project of Bob Duggan of Pharmacyclics fame. This is what keeps our hopes in the future of this company alive, even though the company keeps changing so much ...Nov 8, 2023 · Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call.

Dec 4, 2023 · Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders. Insiders own 29.61% of the company shares, while shares held by institutions stand at 3.27% with a share float percentage of 4.64%. Investors are also buoyed by the number of investors in a company, with Summit Therapeutics Inc having a total of 119 institutions that hold shares in the ...

Cambridge, MA, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that Kenneth A. Clark, JD, has been appointed to our Board of Directors, effective immediately.Web

Oxford, UK, and Cambridge, MA, US, September 17, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) led by billionaire investor Robert W. Duggan as Executive Chairman, Chief Executive Officer and ...WebFind the latest press releases from Summit Therapeutics Inc. Common Stock (SMMT) at Nasdaq.com. Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for …Cambridge, MA, March 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the fourth quarter and full-year ...WebPrincipal Financial Group Inc. purchased a new stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) during the second quarter, according …Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Shares of Summit Therapeutics ( SMMT) were down more than 13% on Tuesday. The biotech company's shares have been trending downward since it released first-quarter earnings late last week. On top ...Hedge fund interest in Summit Therapeutics PLC (NASDAQ:SMMT) shares was flat at the end of last quarter. This is usually a negative indicator. This is usually a negative indicator.Summit Therapeutics (NASDAQ: SMMT) does not pay a dividend. Does Summit Therapeutics have sufficient earnings to cover their dividend?

View live Summit Therapeutics Inc. chart to track its stock's price action. Find market predictions, SMMT financials and market news. 3 de nov. de 2023 ... (NASDAQ: SMMT) (“Summit”) will present data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab (AK112 ...Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK ...Instagram:https://instagram. 2 best vanguard funds for retireesdubais most expensive housegenerac generator stockinvestors alley Fiscal Q3 2023 ended 9/30/23. Reported on 11/7/23. Get the latest Summit Therapeutics Inc (SMMT) real-time quote, historical performance, charts, and other financial information to … online trading platforms canadafun cities in the us Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK. why is pfizer stock so low compared to moderna The public float for SMMT is 111.77M and currently, short sellers hold a 8.48% ratio of that float. The average trading volume of SMMT on November 16, 2023 was 972.70K shares. SMMT) stock’s latest price update. The stock of Summit Therapeutics Inc (NASDAQ: SMMT) has increased by 0.51 when compared to last closing price of 1.97.OXFORD, United Kingdom, March 07, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular ...Web